Stockreport

Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for ...

PROVECTUS BIOPHARMS  (PVCT) 
NASDAQ:AMEX Investor Relations: provectusbio.com/financial-overview
PDF KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of [Read more]